Glenmark enters clinic with 'derisked' early stage pain MAb
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals is moving ahead in the UK with the development of GBR-900, its "derisked" first in class monoclonal antibody for chronic pain targeting tyrosine kinase A (TrkA), the receptor of nerve growth factor (NGF).